EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

An open-label, randomized controlled trial to assess a ketogenic diet in critically ill patients with sepsis

Tim Rahmel iD, David Effinger iD, Thilo Bracht iD, Leonore Griep, Björn Koos iD, Barbara Sitek, Max Hübner iD, Simon Hirschberger iD, Jale Basten iD, Nina Timmesfeld iD, Michael Adamzik, Simone Kreth iD

Science Translational Medicine · 2024

DOI: 10.1126/scitranslmed.adn9285 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Science Translational Medicine, 2024. Verfasst von Tim Rahmel und 11 weiteren Autor:innen. Beteiligte Einrichtung: Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum Knappschaftskrankenhaus Bochum, 44892 Bochum, Germany. Hauptthemen laut MEDLINE: Diet, Ketogenic, Critical Illness, Sepsis. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with sepsis experience metabolic and immunologic dysfunction that may be amplified by standard carbohydrate-based nutrition. A ketogenic diet (KD) may offer an immunologically advantageous alternative, although clinical evidence is limited. We conducted a single-center, open-label, randomized controlled trial to assess whether a KD could induce stable ketosis in critically ill patients with sepsis. Secondary outcomes included assessment of feasibility and safety of KD, as well as explorative analysis of clinical and immunological characteristics. Forty critically ill adults were randomized to either a ketogenic or standard high-carbohydrate diet. Stable ketosis was achieved in all KD patients, with significant increases in β-hydroxybutyrate levels compared with controls [mean difference 1.4 milimoles per liter; 95% confidence interval (CI): 1.0 to 1.8; P < 0.001). No major adverse events or harmful metabolic side effects (acidosis, dysglycemia, or dyslipidemia) were observed. After day 4, none of the patients in the KD group required insulin treatment, whereas in the control group, insulin dependency ranged between 35% and 60% ( P = 0.009). There were no differences in 30-day survival, but ventilation-free [incidence rate ratio (IRR) 1.7; 95% CI: 1.5 to 2.1; P < 0.001], vasopressor-free (IRR 1.7; 95% CI: 1.5 to 2.0; P < 0.001), dialysis-free (IRR 1.5; 95% CI: 1.3 to 1.8; P < 0.001), and intensive care unit–free days (IRR 1.7; 95% CI: 1.4 to 2.1; P < 0.001) were higher in the ketogenic group. Next-generation sequencing of CD4 + /CD8 + T cells and protein analyses showed reduced immune dysregulation, with decreased gene expression of T-cell activation and signaling markers and lower pro-inflammatory cytokine secretion. This trial demonstrated the safe induction of a stable ketogenic state in sepsis, warranting larger trials to investigate potential benefits in sepsis-related organ dysfunction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diet, KetogenicCritical IllnessSepsisHumansMaleFemaleMiddle Aged3-Hydroxybutyric AcidAdultAgedKetosisTreatment Outcome

Substanzen

3-Hydroxybutyric Acid

Autor:innen und Institutionen

  • Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum Knappschaftskrankenhaus Bochum, 44892 Bochum, Germany.
  • Walter Brendel Centre of Experimental Medicine, Ludwig-Maximilian-University Munich (LMU), 81377 Munich, Germany.
  • Department of Anaesthesiology, LMU University Hospital, 81377 Munich Germany.
  • Department of Medical Informatics, Biometry & Epidemiology, Ruhr-University of Bochum, 44780 Bochum, Germany.

ORCID-Profile: Tim Rahmel, David Effinger, Thilo Bracht, Björn Koos, Max Hübner, Simon Hirschberger, Jale Basten, Nina Timmesfeld, Simone Kreth

Zitieren

APA

Rahmel, T., Effinger, D., Bracht, T., Griep, L., Koos, B., Sitek, B., Hübner, M., Hirschberger, S., Basten, J., Timmesfeld, N., Adamzik, M., & Kreth, S. (2024). An open-label, randomized controlled trial to assess a ketogenic diet in critically ill patients with sepsis. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.adn9285

Vancouver

Rahmel T, Effinger D, Bracht T, Griep L, Koos B, Sitek B, et al. An open-label, randomized controlled trial to assess a ketogenic diet in critically ill patients with sepsis. Science Translational Medicine. 2024. doi:10.1126/scitranslmed.adn9285

BibTeX
@article{Rahmel2024,
  author = {Rahmel, Tim and Effinger, David and Bracht, Thilo and Griep, Leonore and Koos, Björn and Sitek, Barbara and Hübner, Max and Hirschberger, Simon and Basten, Jale and Timmesfeld, Nina and Adamzik, Michael and Kreth, Simone},
  title = {An open-label, randomized controlled trial to assess a ketogenic diet in critically ill patients with sepsis},
  journal = {Science Translational Medicine},
  year = {2024},
  doi = {10.1126/scitranslmed.adn9285}
}
Kostenlos starten →